So far, the results of the ongoing clinical study of SOT101 appear to be very promising, with a number of patients having a partial regression of the tumor or complete disappearance of its foci. “The other three anticancer drugs should enter the clinical phase this year,” says Professor Radek Špíšek (46), a prominent immunologist and CEO of Sotio.
Has the fight against covide-19 brought any new insights to immunotherapists? Anticancer immunotherapy is a completely different field. We haven’t learned anything from covid that would affect our thinking compared to tumor immunity. Although I’m a professor of immunology, I tried not to comment on the entire covid pandemic, because basically no one could predict in advance what would happen. However, my colleagues and I looked at the issue of coronavirus as a respiratory virus that the human immune system did not yet know, and it would take about two years before we had some form of immunity – either caused by vaccination or natural infestation. And that if all goes well, after about two years, it will turn into a common respiratory virus and cease to be a scarecrow. This more or less happened, even though the individual countries fought it somewhere worse, somewhere better. However, the great positive news for the general public is that vaccines have been developed at an unprecedented rate. Although they do not provide 100% protection, which is common with frequently changing respiratory viruses, they have clearly helped alleviate the severe course of the disease and gain time until the population is naturally infected.